Lung Cancer Clinical Trials in Arizona

Showing 281-300 of 533 trials

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

NCT05094804

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.

CancerTumor, SolidMalignant Neoplasm+7 more

OncoResponse, Inc.172 participantsStarted Sep 2021

Scottsdale, Arizona, United States • Austin, Texas, United States • San Antonio, Texas, United States

COMPLETEDPhase 133 miles

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

NCT03219268

The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.

Advanced Solid TumorsHematologic NeoplasmsOvarian Cancer+7 more

MacroGenics277 participantsStarted Aug 2017

Gilbert, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +37 more locations

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Lung Cancer Trials in Other Cities

Prospective Clinicogenomic Program

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Survival Prolongation by Rationale Innovative Genomics

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Study of the CD40 Agonistic Monoclonal Antibody APX005M

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

International Lung Screen Trial (ILST)

Other Conditions in Arizona